Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Adherium Ltd. ( (AU:ADR) ) just unveiled an announcement.
Adherium Limited has launched an accelerated non-renounceable pro-rata entitlement offer to eligible retail shareholders, offering one new share for every 1.5 shares held at an issue price of $0.003 per share. The offer aims to raise up to approximately $816,377 before costs, with the retail component scheduled to close on 5 March 2026.
The capital raising is being conducted under section 708AA of the Corporations Act, allowing the company to proceed without a full prospectus while still reminding investors that the booklet is not a disclosure document and does not constitute investment advice. The structure of the offer reinforces Adherium’s reliance on existing shareholders for funding and underscores the risks and uncertainties around future performance that investors must weigh when considering participation.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an ASX-listed company that develops and supplies digital health solutions, with a focus on connected devices and technologies to support patient monitoring and adherence in healthcare. The company targets investors on the Australian Securities Exchange as it seeks to fund its ongoing operations and growth initiatives through equity offerings.
Technical Sentiment Signal: Sell
Current Market Cap: A$21.64M
Learn more about ADR stock on TipRanks’ Stock Analysis page.